

PUBLISHER'S NOTE: Based on the information available to BioMed Central, this article was apparently handled and peer reviewed only by Waseem Jerjes, an Editor-in-Chief of the journal at that time. There were no other peer reviewers.

RESEARCH

Open Access

Definitive radiotherapy for early stage glottic cancer by 6 MV photons

Chi-Chung Tong^{*}, Kwok-Hung Au, Roger Kai-Cheong Ngan, Foon-Yiu Cheung, Sin-Ming Chow, Yiu-Tung Fu, Joseph Siu-Kei Au and Stephen Chun-Key Law

Abstract

Purpose: To evaluate the clinical outcome of early glottic cancer (GC) treated by primary radiotherapy (RT) with 6 MV photons.

Methods and materials: We retrospectively reviewed the medical records of 695 consecutive patients with T1N0 and T2N0 GC treated between 1983 and 2005 by RT in our institution. Clinical outcome in terms of local control (LC), overall survival (OS) and cause-specific survival (CSS) rate were evaluated.

Results: The median follow-up time was 10.5 years. The 10-year actuarial LC rates were as follows: T1A, 91%; T1B, 87%; T2, 77%. The 10-year OS were as follows: T1, 74.2%; T2, 70.7%. The 10-year CSS were as follows: T1, 97.7%; T2, 97.1%.

Poorly differentiated histology and tumor biologically effective dose $< 65 \text{ Gy}_{15}$ were adverse factors in both LC of T1 and T2 disease. Involvement of anterior commissure was an adverse factor in both LC and CSS of T1 disease. Subglottic extension was associated with poor LC in T2 disease whereas hemoglobin < 13.0 was associated with poor LC and CSS of T2 disease.

Conclusion: Primary RT remains an option among the various standard treatments for early GC. Clinical treatment outcome by 6MV photons is similar and comparable to historic data of Cobalt-60 and 2 MV photons.

Keywords: T1/T2N0 glottic cancer, Radiotherapy, 6MV photons, Biologically effective dose

Introduction

Laryngeal cancer is the third most common head and neck (H&N) cancer in Hong Kong. According to Hong Kong Cancer Registry, the age-standardized incidence rate was 2.3 per 100,000 in 2007[1].

In western countries, definitive radiotherapy (RT) and conservative surgery (endoscopic laser surgery/open organ preserving surgery) are accepted standard treatment modalities for early stage laryngeal cancers. The axiom of treatment aims for cure with laryngeal preservation and maintain optimal quality of life like voice quality and swallowing. The choice of treatment depends on availability of facilities and medical expertise, as well as patient's preference and the cost of treatment [2,3].

A survey conducted to eleven Asian regions/countries about management strategy of early laryngeal cancer

revealed that around half of the countries/regions, especially those follow the British stream, like Hong Kong and Singapore, primary radiotherapy remained a mainstay treatment modality [4]. In Hong Kong, around 95% of early glottic cancer (GC) patients were treated by primary radiotherapy (RT) alone.

For definitive RT, there is extensive published data regarding management of early GC with Cobalt-60 or 2-4 MV photons. Factors studied for prognostic importance for local failure included pretreatment hemoglobin [5], sex [5,6], T category [5,7], histology differentiation [7], anterior commissure involvement [6], subglottic extension [5], tumor bulk [5,6,8], fraction dose size [7] and overall treatment time [7].

The reported treatment outcome of early GC by primary RT with 6MV photons is limited. We present our institution's experience in this report.

* Correspondence: chichungtonghkcr.org

Department of Clinical Oncology, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong

Methods and materials

Patient characteristics

In Hong Kong, most citizens are not covered by medical insurance and their medical care is provided mainly by the public care system funded by the Government. The Queen Elizabeth Hospital is one of the major public tertiary referral centers.

In May 2010, we conducted a retrospective review of laryngeal cancer patients referred to our center over a 23 year period for radical treatment between January 1983 to December 2005. A total of 1256 consecutive patients were identified. According to the Hong Kong Cancer Registry, about a quarter of laryngeal cancer cases diagnosed in Hong Kong over that period had been treated in our institution.

Out of the 1256 patients, there were 695 previously untreated patients with T1N0 and T2N0 GC. Six hundred and sixty-two were male and 33 female patients, with a male: female ratio of 20:1. Six hundred and eighty-two (98%) were Chinese and 13 (2%) came from other ethnic backgrounds. Age ranged from 35 to 94 (median: 65). As the treatment of choice at our institution for stage I and II GC has always been primary RT alone, this represented a relatively unselected cohort of patients.

Staging

All patients had full physical examination, routine blood counts, renal and liver function tests, chest x ray, endoscopic examination and biopsy for histology diagnosis. Computed tomography (CT) scan of larynx and neck was performed in 661 (95%) patients. All patients were restaged according to TNM 2002 classification [9]. Table 1 summarizes the patient and tumor parameters.

Radiotherapy treatment

All patients were treated exclusively with 6-MV photons. They were treated in a supine position, immobilized with a customized neck cast. All patients received a continuous course of RT with once-daily fractionation, 5 fractions per week. All fields are equally weighted and treated in each fraction. Appropriate wedge filters were used to improve the dose homogeneity. 0.5 cm wax bolus was used for disease involving the anterior commissure (AC). Table 2 summarizes the treatment parameters.

Field size and set up

T1N0

All patients with T1 disease were treated with parallel-opposed fields, to cover the glottic larynx with 1-2 cm margins. The field size was obtained by multiplying the field length by the field height. They ranged from 22-38.5 cm² (median: 27.5 cm²). Typically, the superior border was placed at around the superior border of the

thyroid cartilage, the inferior border was placed at around the bottom of the cricoid cartilage, the anterior border extending beyond the skin surface and the posterior border stopping at the anterior border of the vertebral body of cervical spine. Elective nodal irradiation was not given.

T2N0

Two hundred and thirty eight (90.8%) of T2 patients were treated with parallel opposed fields. Although the initial field sizes ranged from 35 to 72 cm² (median: 42), 82% of patients were treated with 42 cm² (6 cm x 7 cm) or smaller portals.

Twenty one (8%) patients were treated with a single anterior appositional field, in which electron beam were used after the initial 30 Gy given by 6 MV photon beam. Three (1.1%) patients were treated with a three-field technique by adding an anterior field to two opposing fields.

Dose and fractionation

Dose was prescribed at the midline along the central axis or recalculated at the ICRU reference point. Between the period of 1983- 1988 and 1996- 2005, patients were treated with a fraction size of 2.0 Gy whereas during 1989-1995, a fraction size of 2.5 Gy was utilized because of constraints in linear accelerator machine in the hospital.

To allow comparison of dose prescribed in different periods, we opted to compute the tumor biologically effective dose (BED) by using the standard linear quadratic formula (LQ) with time factors corrected [10]:

$$\text{Tumor BED} = nd(1 + d/[\alpha/\beta]) - \log_e 2 (T - Tk)/\alpha T_p$$

where n fractions of d Gy are given in an overall time of T days and kick off time (T_k) for tumor repopulation. We assume $\alpha/\beta = 15$ for laryngeal cancer [11], $T_k = 28$ for tumor [12], $T_p =$ average cell number doubling time during continuing radiation, 3 days for tumor [13]. Alpha (α) = 0.35 Gy⁻¹ [13] [coefficient of non-repairable injury, log cell kill (exponentially-based logs) per gray of dose].

T1N0

During 1983-1988 and 1996-2005, the dose-fractionation schedule was 66 Gy in 33 fractions whereas during 1989- 1995, the schedule was 57.5 Gy in 23 fractions.

T2N0

During 1983 - 1988, the dose- fractionation schedule was 66 Gy in 33 fractions whereas during 1989-1995, the schedule was 57.5 Gy in 23 fractions. Since 1996, we have prescribed up to 70 Gy in 35 fractions for all T2 disease.

Follow up and assessment

All patients underwent evaluation of response to treatment by endoscopy examination at 6 to 8 weeks after completion of RT treatment. Patients were regularly seen once every three months during the initial 2 years and then six-monthly up to 5 years and then yearly thereafter.

Complications

Acute and chronic complications were scored according to the Common Terminology Criteria for Adverse Events version 3.0 [14].

Statistical analysis

Local and neck failure was defined as clinically/radiological detectable disease in larynx and cervical lymph node (LN) respectively. Distant metastasis (DM) was defined as clinically or radiologically detectable disease outside the larynx and cervical LN. Clinicopathologic parameters that were analyzed included age (<61 vs. 61-70 vs. >71), gender (male vs. female), pre-treatment hemoglobin (Hb) level (<13.0 vs. ≥13.0 g/dl), T sub-stage (T1a vs. T1b) [for T1 disease], impaired cord mobility (yes

Table 1 Patient and tumor parameters

Parameter	T1N0 Patient no. (%)	T2N0 Patient no. (%)
All stages	433	262
T1a	324 (74.8%)	-
T1b	109 (25.1%)	-
Gender		
Male	413 (95.3%)	249 (93.8%)
Female	20 (4.6%)	13 (4.9%)
Grade		
Well differentiated	154 (35.5%)	64 (24.4%)
Mod differentiated	273 (63.0%)	179 (68.3%)
Poorly differentiated	6 (1.3%)	19 (7.2%)
Anterior commissure involved		
Yes	197 (45.4%)	186 (71%)
No	236 (54.1%)	76 (29%)
Impaired mobility		
Yes	Not apply	51 (19.4%)
No		211 (80.5%)
Sub-glottic extension		
Yes	Not apply	80 (31%)
No		182 (69%)
Hb level		
< 13 g/dL	45 (10.4%)	28 (10.6%)
≥ 13 g/dL	388 (89.6%)	234 (91.4%)

Abbreviations: no. = number; Hb = Hemoglobin.


Table 2 Treatment parameters

Parameters	Stage T1N0 (433) Patients (%)	Stage T2N0 (262) Patients (%)
Field size (cm ²)		
< 30.5	215 (49.6)	0
30.5- 35.5	165 (38.1)	106 (40.4)
≥ 35.5	53 (12.2)	156 (59.5)
A. Dose fraction size		
2.5 Gy	177 (40.8)	86 (32.8)
Total dose (Gy)		
55	30 (6.9)	7 (2.7)
57.5	134 (30.9)	63 (24.0)
60	13 (3.0)	16 (6.1)
Tx duration (days)		
30	25 (5.7)	22 (8.4)
31-34	141 (32.5)	45 (17.1)
≥ 35	11 (2.5)	19 (7.2)
BEDcGy ₁₅ (cGy)		
Median	6520	6580
range	6058- 6820	6160- 6820
B. Dose fraction size		
2.0 Gy	256 (59.1)	176 (67.1)
Total dose (Gy)		
64	52 (12.0)	24 (9.1)
66	202 (46.6)	109 (41.6)
68	2 (0.46)	2 (0.7)
70	0	41 (15.6)
Tx duration (days)		
≤45	48 (11.0)	18 (6.8)
46- 50	203 (46.8)	110 (42.0)
≥ 51	5 (1.15)	48 (18.3)
BEDcGy ₁₅ (cGy)		
Median	6340	6520
range	6040- 6700	6040- 6910

Abbreviations: Tx = treatment; BED = biologically effective dose.


vs. no) [for T2 disease], tumor grading (well vs. moderate vs. poorly differentiated squamous cell carcinoma) and involvement of AC (yes vs. no). Treatment parameters included dose fraction size (2.0 Gy vs. 2.5 Gy), BEDGy₁₅ given (<65.0 Gy₁₅ vs. ≥ 65.0 Gy₁₅), treatment field size in cm² (< 30.5 vs. 30.5 – 35.5 vs. > 35.5), and treatment period (1983- 1990 vs. 1991- 2000 vs. 2001- 2005).

All time-related events were measured from date of the first RT treatment. The actuarial local control (LC) rate, ultimate LC rate, cause- specific survival (CSS) and overall survival (OS) were calculated by the Kaplan-Meier method. Difference of the endpoints of patient cohorts stratified by various prognostic factors were evaluated by the Log- rank



test. Cox proportional hazard model was used for both univariate and multivariate analysis to determine the hazard ratios and significance of potential risk factors for LC and CSS. All statistical tests were two-sided and

performed at the 0.05 level of significance (p value). Only factors with a level of significance less than 0.05 in univariate analysis would be further analyzed in the multivariate analysis. We used SPSS, version 15.0, (SPSS Inc., Chicago, IL) for all statistical analyses.



Results

Local and neck control

The clinical course of this patient cohort is shown in Figure 1. The median follow-up period was 10.5 years (range: 3.3-26 years). LC after primary RT is depicted in Figure 2. The 5-year and 10-year actuarial LC rates were as follows: T1A, 92% and 91%; T1B, 89% and 87%; T2, 79% and 77% respectively.

Complete response was achieved in 679 (97.6%) patients, while 16 (2.3%) patients (3 T1 and 13 T2) had residual disease at vocal cord(s). Seventy three (10.5%) among the 679 patients who achieved complete response had first relapse with a median time of 15 months. The first sites of relapse included: vocal cord(s) only in 68

Table 3 Univariate and multivariate analysis of factors affecting local control

Parameters	Event/pts	T1N0			Event/pts	T2N0		
		Uni-variate	Multivariate analysis			Uni-variate	Multivariate analysis	
		P value	Hazard ratio (95% CI)	P value		P value	Hazard ratio (95% CI)	P value
Age								
<61	18/142	0.302	-	NS	22/90	0.747	-	NS
61-70	15/153				23/103			
>70	9/138				13/69			
Sex								
Male	41/413	0.445	-	NS	55/249	0.831	-	NS
Female	1/20				3/13			
Substage								
T1A	28/324	0.24	-	NS	NA	-	-	-
T1B	14/109							
Grade								
Well diff	9/154	0.0001*	1	0.035*	10/64	0.025*	1	
Moderate diff	29/273		1.91 (1.2- 3.85)		40/179		2.4 (1.7- 3.2)	0.022*
Poorly diff	4/6		7.5(3.42- 5.24)		8/19		4.3(2.6- 8.9)	
Impaired Cord mobility								
yes	NA	-	-	-	11/51	0.53	-	NS
No					47/211			
Subglottic Extension								
Yes	NA	-	-	-	23/80	0.038*	2.15 (1.78-5.51)	0.027*
No					35/182		1	
Hb (g/dL)								
< 13.0	6/45	0.367	-	NS	15/28	0.001*	3.78 (1.34-8.40)	0.031*
≥ 13.0	36/388				43/234		1	
AC								
No	14/236	0.004*	1	0.011*	12/76	0.129	-	NS
Yes	28/197		2.34 (1.21-4.52)		46/186			
Field size (cm ²)								
<30.5	35/215	0.534	-	NS	0	0.138	-	NS
30.5- 35.5	7/165				26/106			
> 35.5	0/53				32/156			
Dose size								
2.0 Gy	32/256	0.021*	2.17 (1.28- 4.18)	0.035*	45/176	0.042*	-	NS
2.5 Gy	10/177		1		13/86			
BEDG ₁₅								
< 65.0	36/315	0.025*	3.38 (1.29- 7.83)	0.017*	12/76	0.022*	1.8 (1.2- 5.74)	0.038*
≥ 65.0	6/118		1		46/186		1	
Tx period								
1983- 1990	10/115	0.643	-	NS	17/75	0.336	-	NS
1991- 2000	25/224				29/142			
2001- 2005	7/94				12/45			

Abbreviations: pts = patients; Hb = hemoglobin; Tx = treatment; diff = differentiated; AC = anterior commissure; BED = biologically effective dose; * = statistically significant; NS = not significant.

Table 4 Salvage surgery performed

Stage	No of pts	1 st Failures pts				Types of 1 st salvage surgery (No. salvaged/No. attempted)				2nd Relapse Pts	2nd salvage surgery (No salvage/attempted)	Ultimate failure Pts (%)
		local LN	Local + LN	Total (%)	TL	RND	TL + RND	Not fit/refused surgery				
T1	433	39	0	0	39 (9)	36	0	0	3	7	0/7	10 (2.3)
T2	262	45	2	3	50 (19%)	43	2	2	3	3	2/3 (PLO)	7 (2.6)

Abbreviations: No = number; pts = patients; 1st = first; 2nd = second; LN = lymph node; TL = total Laryngectomy RND = radical neck dissection; PLO = pharynolaryngectomy.

(10%) patients (38 T1 and 30 T2), regional LN only in 2 (0.2%) patients (2 T2), vocal cord(s) plus regional LN in 3 (0.4%) patients (3 T2).

Table 3 showed parameters that have prognostic significance on LC. For T1 disease, on multivariate analysis, LC was adversely affected by the poorly differentiated histology (Hazard Ratio [HR]: 7.5, $p = 0.035$), involvement of AC (HR: 2.34, $p = 0.011$), fraction dose size of 2.0 Gy (HR: 2.17, $p = 0.035$) and tumor BED $G_{y15} < 65.0$ G_{y15} (HR: 3.38, $p = 0.017$).

For T2 disease, on multivariate analysis, LC was adversely affected by poorly differentiated grading (HR: 4.3, $p = 0.022$), Hb < 13.0 (HR: 3.78, $p = 0.031$), subglottic extension (HR: 2.15, $p = 0.027$) and tumor BED $G_{y15} < 65.0$ G_{y15} (HR: 1.8, $p = 0.038$).

Salvage surgery and ultimate control

Table 4 showed the details of the radical salvage surgery performed for the 83 patients with residual disease or first relapses. Ultimate disease control was achieved in 678 (97.5%) patients. The 10-year ultimate LC rates for T1 and T2 disease was 97.6% and 97.4% respectively. Larynx preservation was achieved in 606 (87%) patients.

Survival

At the last follow up, 272 patients had died: 15 from glottic carcinomas, 118 from second malignancy and 138 from

intercurrent disease. Figures 3 and 4 showed the OS and CSS for the entire cohort respectively. For T1 disease, multi-variate analysis showed involvement of AC is the only independent adverse factor for CSS (HR: 3.7, $p = 0.045$). For T2 disease, haemoglobin <13.0 is the only independent adverse factor for CSS (HR: 2.8, $p = 0.028$) [Table 5].

Complications

Regarding acute radiation toxicity, there was no incidence of grade 3 or higher acute complications in T1 disease. For T2 disease, 9 (1.2%) patients experienced grade 3 acute radiation toxicity, with an incidence of 9/86 [10.4%] in patients treated with 2.5 Gy compared with none in those treated with 2.0 Gy (chi-square test value: $p = 0.001$). Eight of them had severe odynophagia and grade III confluent mucositis, requiring nasogastric tube feeding or admission for intravenous fluid supplement. All of them needed treatment interruption of more than 4 treatment days. One patient developed grade IV laryngeal edema and necessitated temporary tracheostomy during the last week of RT and ultimately treatment was prematurely terminated after 55 Gy delivered over 22 fractions. There is no treatment death related to acute radiation toxicity. For chronic complication, no clinical or radiological chondroradionecrosis that warrants laryngectomy has been observed.




Figure 3 Overall survival.




Figure 4 Cause specific survival.

Table 5 Univariate and multivariate analysis of factors affecting cause specific survival

Parameters	Event/ pts	T1N0			Event/pts	T2N0		
		Uni-variate	Multivariate analysis			Uni-variate	Multivariate analysis	
		P value	Hazard ratio (95% CI)	P value		P value	Hazard ratio (95%CI)	P value
Age								
<61	4/142	0.897	-	NS	0/90	0.224	-	NS
61-70	3/153				3/103			
>70	3/138				2/69			
Sex								
Male	10/413	0.459	-	NS	5/249	0.61	-	NS
Female	0/20				0/13			
Substage								
T1A	7/324	0.53	-	NS	NA	-	-	-
T1B	3/109							
Grade								
Well diff	3/154	0.825	-	NS	1/63	0.721		NS
Mod diff	7/273				3/179			
Poorly diff	0/6				1/20			
Impaired Cord mobility								
yes	NA	-	-	-	1/51	0.84		NS
No					4/211			
Subglottic Extension								
Yes	NA	-	-	-	2/80	0.56	-	NS
No					3/182			
Hb (g/ dL)								
< 13.0	1/45	0.76	-	NS	1/28	0.022*	2.8 (1.5-7.8)	0.028*
≥ 13.0	9/388				4/234		1	
AC								
No	2/236	0.026*	1	0.045*	1/76	0.712	-	NS
Yes	8/197		3.7 (1.20-18.5)		4/186			
Field size (cm ²)								
<30.5	6/217	0.642	-	NS	0	0.42	-	NS
30.5- 35.5	4/165				2/106			
> 35.5	0/53				3/156			
Dose size								
2.0 Gy	7/256	0.463	-	NS	4/176	0.513	-	NS
2.5 Gy	3/177				1/86			
BED Gy ₁₅								
< 65.0	8/315	0.661	-	NS	4/175	0.534	-	NS
≥ 65.0	2/118				1/87			
Tx period								
1983- 1990	1/115	0.287	-	NS	0/75	0.334	-	NS
1991- 2000	6/224				4/142			
2001- 2005	3/94				1/45			

Abbreviations: pts = patients; Hb = hemoglobin; Tx = treatment; diff = differentiated AC = anterior commissure; BED = biologically effective dose; * = statistically significant; NS = not significant.

Table 6 Published local control and survival rate of early GC treated with 6 MV definite radiotherapy

Author (year)	Patient number	Local Control (%)	OS (%)	CSS (%)
[ref]		5 year*, 10 year #	5 year *, 10 year#	5 year*, 10 year#
Warde et al. [5]	T1 + T2: 72	T1a: 91* T1b: 82* T2: 69*	T1 + T2: 75.8*	NA
Lee et al. [18]	T1: 86 T2: 29	T1a: 82.2* T1b: 76.2* T2: 68.1*	T1: 85* T2: 74*	NA
Franchin et al. [23]	T1: 323 T2: 87	T1: 90# T2: 78#	T1: 66# T2: 55#	NA
Cellai & Frata et al. [6,7]	T1: 35 T2: 68	T1: 84*, 83# T2: 73*, 70#	T1: 77*, 57# T2: 59*, 37#	T1: 95*, 93# T2: 89*, 86#
Chera et al. [8]	T1 + T2: 23	T1a: 94*, 93# T1b: 93*, 91# T2a: 80*, 80# T2b: 70*, 67#	T1 a: 82*, 62# T1b: 83*, 57# T2a: 76*, 51# T2b: 78*, 49#	T1a: 97*, 97# T1b: 99*, 95# T2a: 94*, 93# T2b: 90*, 84#
Current series	T1: 433 T2: 262	T1a: 92*, 91# T1b: 89*, 87# T2: 79*, 77#	T1: 89*, 74# T2: 89*, 70#	T1: 98*, 97# T2: 98*, 97#

Abbreviations: yr = year; NA = not available; OS = overall survival; CSS = cause specific survival.

Discussion

The debate on the optimal treatment options for early GC has a long history, mainly because of absence of definitive prospective randomized trials for comparing the various treatment options [15]. A survey conducted in eleven regions/countries in Asia revealed that in regions following the 'British school' like Hong Kong and Singapore, RT alone has remained the primary treatment modality for early laryngeal cancers [4]. Vlantis et al. reviewed the treatment results of laryngeal carcinoma in a single institution in Hong Kong [16]. For early stage (T1 & T2) glottic lesions, primary RT remained their mainstay of treatment.

As laser surgery become more popular since Steiner's landmark report [17], it is expected that it will be more popular in local localities.

Focusing on primary irradiation, in many RT centers, Cobalt 60 or 2-4 MV X-rays machines have been decommissioned. It is anticipated that 6 MV photon beams generated by LA will become the prevailing work-horse for treatment in clinical practice [18]. Table 6 summarizes the published outcome results of early GC treated with 6 MV photons.

There have been concerns about possible tumor under-dosage when using 6MV or higher energy photons for early GC. It has been reported that the lack of electronic equilibrium at the air-tissue interface in the laryngeal air cavity is more pronounced with both higher-energy X rays and with small field size [19]. The other issue is the lack of adequate buildup tissue in the area where the neck is thin [20]. Izuno et al. observed a significant inferior 5-year LC rate for T1N0 GC patients when treated with 8/10-MV photons compared to Co60 (60% vs. 88%)[21].

Factors affecting local control

T1 disease

The factors of AC involvement, fraction dose size and time dose factor affecting the LC rate of T1 disease has been discussed in a separate article [22].

T2 disease

As noted, the LC rate of T2 disease treated with fractional dose size of 2.5 Gy was superior to those treated with fraction size of 2.0 Gy. However, this significance is lost in

Table 7 Tumor, acute mucosal and late normal BED for two fractionation scheme

Dose size (Gy)	Fraction number	Total dose (Gy)	Overall treatment time (OTT) in days	Tumor BED (Gy ₁₅)	Acute Mucosal BED (Gy ₁₀) (aim 59-63 Gy ₁₀)[13]	Late normal BED (Gy ₃) (aim <117 Gy ₃)[13]
2.0	35	70	47	66.79	52.32	117
2.5	23	57.5	31	65.28	52.87	105.4

Abbreviations: BED = biologically effective dose.

multi-variate analysis. We believe that the tumor BEDGy₁₅ is the key factor to explain the significant difference which is confirmed by the multi-variate analysis.

As shown in Table 7, the fractionation schedule of 2.5 Gy x 23 daily fractions can achieve a tumor BEDGy₁₅ ≥ 65 Gy₁₅, however, it can also be associated with a significant higher incidence of grade 3 acute radiation toxicity as shown by the higher BEDGy₁₀ for acute mucosa and larger treatment field size in T2 disease.

Unlike our recommendation of using a fraction size of 2.5 Gy for T1 disease [22], our current practice for T2 disease is to prescribe 70 Gy in 35 fractions, 2 Gy per fraction, 5 daily fractions per week. This can achieve a tumor BED ≥ 65 Gy₁₅ without an excess of grade 3 acute mucosal toxicity.

Anaemia, poor differentiation of tumor grade and subglottic extension are known reported adverse prognostic factors in LC of GC [5,7,8].

The impact of impaired cord mobility on LC of T2N0 GC is still controversial. Our data is consistent with other published results that reported no prognostic significance on LC [23,24]. However, other studies, including a meta-analysis did suggest its adverse impact on LC [7,25,26].

In view of the relatively inferior LC rate of T2 compared with T1 disease, more intensive treatment strategies are being explored. The role of bid hyperfractionation schedule will become clear when the mature result of RTOG 95-12 study become available. Another approach is the use of concurrent chemotherapy. Nevertheless, there are some data showing improvement of LC by platinum/5FU based regimens [27,28] but others showed conflicting results [29,30].

There are still controversies over the use of Intensity-Modulated Radiotherapy (IMRT) for early stage GC. Feigenberg et al. warned about the treatment failure seen in patient with early GC who received definite RT with IMRT technique [31]. Their concerns were mainly errors due to contouring errors and organ motion.

Some technical studies revealed IMRT technique permit more irradiation dose sparing at carotid arteries and might have favorable implication on long term risk of cerebrovascular accident [32,33]. However, others still continue to recommend conventional RT fields and technique for treatment of patient with early stage GC [34,35].

Conclusion

To the best of our knowledge, our report is the largest study on RT outcomes in early GC primarily treated with 6 MV photons. Both the LC and CSS rates of T1 and T2 disease in our series are comparable with other reported data. This reassures the efficacy of 6 MV photons used in primary RT for early GC. Nevertheless,

the results of the current report is a retrospective, single institution study and therefore can be subjected to biases, especially other known significant prognostic factors including tumor volume and smoking details are lacking. Prospective measurement of voice quality is also not available in this retrospective review.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CCT participated in the study's design and coordination, performed acquisition of data and drafted the manuscript. KHA and FYC participated in data analysis and revised the manuscript. RKC and SMC participated in study's design and revised the manuscript. JSKA, YTF and SCKL revised manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Received: 22 April 2012 Accepted: 29 April 2012

Published: 18 May 2012

References

1. Hospital Authority: Hong Kong Cancer Registry web site: [http://www3.ha.org.hk/cancereg/statistics.html].
2. Pfister DG, Laurie SA, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre JL, Leupold N, List MA, O'Malley BO, Patel S, Posner MR, Schwartz MA, Wolf GT: **American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer.** *J Clin Oncol* 2006, **24**:3693-3704.
3. Kaanders JH, Hordijk GJ: **Carcinoma of the larynx: the Dutch national guideline for diagnostics, treatment, supportive care and rehabilitation.** *Radiother Oncol* 2002, **63**:299-307.
4. Wei W: **Management of early carcinoma of the larynx: the Asian perspective.** *ENT News* 2000, **9**:18-19.
5. Warde P, O'Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ, Witterick IP, Payne D, Liu FF, McLean M, Waldron J, Cummings BJ: **T1/T2 Glottic Cancer Managed by External Beam Radiotherapy: The Influence of Pretreatment Hemoglobin on Local Control.** *Int J Radiat Oncol Biol Phys* 1998, **41**:347-353.
6. Cellai E, Frata P, Magrini SM, Palar F, Barca R, Fondelli S, Polli C, Livi L, Bonetti B, Vitali E, De Stefani A, Buglioni M, Biti G: **Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease.** *Int J Radiat Oncol Biol Phys* 2005, **63**:1378-1386.
7. Chera BS, Amdur RJ, Morris CG, Kirwan JM, Mendenhall WM: **T1N0 to T2N0 Squamous Cell Carcinoma of the Glottic Larynx Treated With Definitive Radiotherapy.** *Int J Radiat Oncol Biol Phys* 2010, **78**:461-466.
8. Frata P, Cellai E, Magrini SM, Bonetti B, Vitali E, Tonoli S, Buglioni M, Palar F, Barca R, Fodelli S, Polli C, Livi L, Biti G: **Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease.** *Int J Radiat Oncol Biol Phys* 2005, **63**:1387-1394.
9. Sobin LH, Wittekind CH: *UICC TNM Classification of malignant tumours.* 6th edition. New York: John Wiley & Sons; 2002.
10. Fowler JF: **The linear-quadratic formula and progress in fractionated radiotherapy.** *Br J Radiol* 1989, **62**:679-694.
11. Robertson AG, Robertson C, Boyle P, Symonds RP, Wheldon TE: **The effect of differing radiotherapeutic schedules on the response of glottic carcinoma of the larynx.** *Eur J Cancer B Oral Oncol* 1993, **29A**(4):501-510.
12. Skladowski K, Law MG, Maciejewski B, Steel GG: **Planned and unplanned gaps in radiotherapy: The importance of gap position and gap duration.** *Radiother Oncol* 1994, **30**(2):109-120.
13. Fowler JF: **21 years of Biologically Effective Dose.** *Br J Radiol* 2010, **83**:554-568.
14. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: **CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.** *Semin Radiat Oncol* 2003, **13**(3):176-181.

15. Dey P, Arnold D, Wight R, MacKenzie K, Kelly C, Wilson J: *Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer (Review)*. Library: The Cochrane; 2010.
16. Vlantis AC, Yu BK, Tsang RK, Kam MK, Lo PS, van Hasselt CA: **Laryngeal carcinoma: five-year survival and patterns of failure in 202 consecutive patients treated with primary or post-operative radiotherapy in Hong Kong.** *J Laryngol Otol* 2006, **120**:397–404.
17. Steiner W: **Results of curative laser microsurgery of laryngeal carcinomas.** *Am J Otolaryngol* 1993, **14**:116–121.
18. Lee JH, Machtay M, McKenna MG, Weinstein GS, Markiewicz DA, Krisch RE, Kligerman WM: **Radiotherapy with 6-megavolt photons for early glottic carcinoma: Potential impact of extension to the posterior vocal cord.** *Am J Otolaryngol* 2001, **22**(1):43–54.
19. Epp ER, Boyer AL, Doppke KP: **Underdosing of lesions resulting from lack of electronic equilibrium in upper respiratory air cavities irradiated by 10 MV X-ray beams.** *Int J Radiat Oncol Biol Phys* 1977, **2**:613–619.
20. Klein EE, Chin LM, Rice RK, Mijneer BJ: **The influence of air cavities on interface doses for photon beams.** *Int J Radiat Oncol Biol Phys* 1993, **27**(2):419–427.
21. Izuno I, Sone S, Oguchi M, Kiyono K, Takei K: **Treatment of early vocal cord carcinoma with 60 CO gamma rays, 8/10 MV X-rays, or 4 MV X-rays – are the results different?** *Acta Oncol* 1990, **29**(5):637–639.
22. Tong CC, Au KH, Ngan RK, Chow SM, Cheung FY, Au JS, Law SC: **Impact and relationship of anterior commissure and time-dose factor on the local control of T1N0 glottic cancer treated by 6 MV photons.** *Radiat Oncol* 2011, **6**:53.
23. Franchin G, Minatel E, Gobitti C, Talamini R, Vaccher E, Sartor G, Politi D, Trovö MG, Barzan L: **Radiotherapy for patients with early-stage glottic carcinoma: univariate and multivariate analyses in a group of consecutive, unselected patients.** *Cancer* 2003, **98**(4):765–772.
24. Garden AS, Forster K, Wong PF, Morrison WH, Schechter NR, Ang KK: **Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment?** *Int J Radiat Oncol Biol Phys* 2003, **55**(2):322–328.
25. McCoul ED, Har-El G: **Meta-analysis of Impaired Vocal Cord Mobility as a Prognostic Factor in T2 Glottic Carcinoma.** *Arch Otolaryngol Head Neck Surg* 2009, **135**(5):479–486.
26. Smee RI, Meagher NS, Williams JR, Broadley K, Bridger GP: **Role of radiotherapy in early glottic carcinoma.** *Head & Neck* 2010, **32**(7):850–859.
27. Akimoto T, Nonaka T, Kitamoto Y, Ishikawa H, Ninomiya H, Chikamatsu K, Furuya N, Hayakawa K, Mitsuhashi N, Nakano T: **Radiation therapy for T2N0 laryngeal cancer: A retrospective analysis for the impact of concurrent chemotherapy on local control.** *Int J Radiat Oncol Biol Phys* 2006, **64**(4):995–1001.
28. Nishimura G, Tsukuda M, Mikami Y, Matsuda H, Horiuchi C, Taguchi T, Takahashi M, Kawakami M, Watanabe M, Niho T, Abo H, Yamamoto S: **Efficacy of Concurrent Chemoradiotherapy for T1 and T2 Laryngeal Squamous Cell Carcinoma Regarding Organ Preservation.** *Anticancer Res* 2009, **29**(2):661–666.
29. Murakami R, Nishimura R, Baba Y, Yumoto E, Oya N, Ymashita Y: **Concurrent chemoradiation therapy with low-dose CDDP and UFT for glottic carcinomas: Evaluation using the sixth edition of the UICC TNM staging system.** *Acta Oncologica* 2006, **45**:162–167.
30. Hirasawa N, Itoh Y, Ishihara S, Kubota S, Itoh J, Fujimoto Y, Nakashima T, Naganawa S: **Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis.** *Head & Neck Oncology* 2010, **2**:20.
31. Feigenberg SJ, Lango M, Nicolaou N, Ridge JA: **Intensity-Modulated Radiotherapy for Early Larynx Cancer: Is There a Role?** *Int J Radiat Oncol Biol Phys* 2007, **68**(1):2–3.
32. Gomez D, Cahlon O, Mechalakos J, Lee N: **An investigation of intensity-modulated radiation therapy versus conventional two-dimensional and 3D-conformal radiation therapy for early stage larynx cancer.** *Radiat Oncol* 2010, **5**:74.
33. Rosenthal DI, Fuller CD, Barker JL, Mason B, Garcia JA, Lewin JS, Holsinger FC, Stasney CR, Frank SJ, Schwartz DL, Morrison WH, Garden AS, Ang KK: **Simple Carotid-Sparing Intensity-Modulated Radiotherapy Technique and Preliminary Experience for T1–2 Glottic Cancer.** *Int J Radiat Oncol Biol Phys* 2010, **77**(2):455–461.
34. Chera BS, Amdur RJ, Morris CG, Mendenhall WM: **Carotid-Sparing Intensity-Modulated Radiotherapy for Early-Stage Squamous Cell Carcinoma of the True Vocal Cord.** *Int J Radiat Oncol Biol Phys* 2010, **77**:1380–1385.
35. Tjong AC, Huang S, O'Sullivan B, Xu W, Kim J, Dawson LA, Cho J, Gilbert R, Breen S, Waldron JN: **Outcomes for T2N0M0 Glottic Squamous Cell Carcinoma Treated with IMRT Compared with Conventional Parallel Opposed Fields.** *Int J Radiat Oncol Biol Phys* 2011, **81**:S106–S107.

doi:10.1186/1758-3284-4-23

Cite this article as: Tong et al.: Definitive radiotherapy for early stage glottic cancer by 6 MV photons. *Head & Neck Oncology* 2012 **4**:23.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

